Can nonsteroidal anti-inflammatory drugs (NSAIDs) be safely administered to patients with multiple sclerosis (MS)?

NSAIDs Can Be Safely Given to Patients with Multiple Sclerosis

Yes, NSAIDs can be administered to patients with MS for pain management, with naproxen and ibuprofen showing particular effectiveness for MS-related symptoms, though standard cardiovascular and gastrointestinal precautions apply.

Evidence from MS-Specific Research

The most direct evidence comes from a randomized controlled trial specifically examining pain medications in MS patients 1. This study evaluated naproxen, ibuprofen, and acetaminophen in 60 MS patients on interferon beta-1a therapy and found:

• Naproxen and ibuprofen were more effective than acetaminophen in minimizing physical side effects
• Both NSAIDs improved physical functioning scores significantly (p=0.002 for naproxen, p<0.01 for ibuprofen)
• No MS-specific safety concerns emerged during the 5-week treatment period

A more recent mixed-methods study 2 of 899 MS patients with regular pain found that 87.3% used pain medications, with NSAIDs (alone or in combination with acetaminophen) among the commonly reported effective medications. The study noted that 62.3% of all medications provided acceptable pain relief, with medication discontinuation primarily due to side effects or ineffectiveness—not MS-specific complications.

Standard NSAID Precautions Apply

While there are no MS-specific contraindications to NSAIDs, the standard cardiovascular and gastrointestinal risks remain relevant 3, 4:

Cardiovascular Considerations:

• Avoid NSAIDs in patients with established cardiovascular disease or significant risk factors
• If NSAIDs are necessary in cardiac patients, use naproxen as the preferred agent (lowest cardiovascular risk among NSAIDs)
• Use the lowest effective dose for the shortest duration
• Monitor blood pressure (expect average 5 mmHg increase)

Gastrointestinal Protection:

• Consider proton pump inhibitor co-prescription in patients with:
  • History of GI bleeding or ulcers
  • Age >65 years
  • Concurrent anticoagulant or corticosteroid use
  • High-dose or prolonged NSAID therapy

Renal Monitoring:

• Use caution when combining with ACE inhibitors, ARBs, or diuretics
• Avoid in patients with pre-existing renal impairment
• Monitor renal function if prolonged use is necessary

Practical Recommendations for MS Patients

For acute MS relapse-related pain or chronic MS-associated pain:

1. First-line: Acetaminophen (up to 4g/day) for mild pain
2. Second-line: Naproxen or ibuprofen if acetaminophen insufficient
   • Naproxen: 220-500mg twice daily
   • Ibuprofen: 400-600mg three times daily
3. Duration: Use for shortest time necessary; short-term use (≤10 days) carries minimal risk 5
4. Monitoring: Assess cardiovascular risk factors, GI history, and renal function before initiating

Important Caveats

• NSAIDs do not affect MS disease activity or progression—they are purely symptomatic treatments 6
• The anti-inflammatory properties of NSAIDs do not translate to disease-modifying effects in MS, despite theoretical interest in neuroinflammation 7
• Do not delay or substitute disease-modifying therapy with NSAIDs
• MS patients on corticosteroids for acute relapses require enhanced GI protection if NSAIDs are co-administered

The evidence supports NSAID use in MS patients following the same risk-benefit assessment used in the general population, with naproxen and ibuprofen showing specific efficacy for MS-related symptoms.